Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: jayhawk969 who wrote (18761)	4/7/1998 9:05:00 AM
From: Arthur Radley	Read Replies (1) \| Respond to of 32384

They say timing is everything. Would it not be a fantastic event if the following news release had not be offered on February 11, 1998 but instead, issued on April 6, 1998: STUDY IN ANIMAL MODEL DEMONSTRATES TARGRETIN MORE EFFECTIVE THAN TAMOXIFEN;LIGAND EVALUATES PHASE II CLINICAL TRIALS FOR BREAST CANCER San Diego, Feb. 11---Targretin(tm) (LGD 1069), a member of an increasingly important new class of drugs called retinoids, caused complete regression in 72 percent of established breast cancer tumors in one of the most commonly used rat models of this disease, according to a study published by scientists from Ligand Pharmaceuticals Inc. in the current issue of Cancer Research.

To: jayhawk969 who wrote (18761)	4/7/1998 10:07:00 AM
From: tonyt	Respond to of 32384

><Too bad that none of the 20+ press releases posted had any mention of LGND.> > Yes it is too bad. However, the positive is the tremendous amount of > press created around this release. Agreed, but again, too bad the 20+ press releases had nothing to do with Ligand.

To: jayhawk969 who wrote (18761)	4/7/1998 10:13:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

JD, LLY has moved up sharply this morning. It's remarkable that some still put up posts indicating that the press releases have nothing to do with LGND. The LLY/LGND deal not only targets Rexinoids for metabolic diseases, but it also has a program to research combining a SERMs like Evista (Raloxifene) with rexinoids like Targretin.

To: jayhawk969 who wrote (18761)	4/7/1998 10:17:00 AM
From: tonyt	Read Replies (1) \| Respond to of 32384

I guess the 'street' does connect the 20+ press releases to LGND -- its up 1/16th :-) As I typed this, LGND dropped again -- down 3/16ths

To: jayhawk969 who wrote (18761)	4/7/1998 10:26:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

JD, As you know, the street is very slow. ZEN was up over 7 yesterday and it's down over 7 today (and nothing has changed - the Tamoxifen story came out over the weekend). LLY move up a little yesterday and even more today. Most readers of this board know about the the connection between LGND and Evista, Droloxifene, CP-366,156, TSE424 as well as the relationship between between the SERMs and Rexinoids. Other the other hand, some who regularly post here are STILL clueless about LGND's technology, and the street has been a bit slow on the pickup for several years now.